Current strategies to improve the efficacy and the delivery of nucleic acid based drugs

Current Signal Transduction Therapy

Volumn 5, Issue 2, 2010, Pages 92-120

  Grassi, M ^a   Cavallaro, G ^b   Scire S ^b   Scaggiante, B ^a   Dapas, B ^c   Farra, R ^d   Baiz, D ^a   Giansante, C ^c   Guarnieri, G ^c   Perin, D ^a,e   Grassi, G ^a,c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d Division of Internal Medicine   (Italy)

^e PROTOS Research Institute   (Italy)

Author keywords

Delivery; Nucleic acid based drugs; Therapeutic potential

Indexed keywords

ANGIOZYME; ANTISENSE OLIGONUCLEOTIDE; APTAMER; AS 1411; AVI 4126; CYCLODEXTRIN; DECOY OLIGODEOXYNUCLEOTIDE; DENDRIMER; DNAZYME; FOMIVIRSEN; HAMMERHEAD RIBOZYME; I KAPPA B KINASE INHIBITOR; LIPID; LIPOSOME; NANOPARTICLE; NUCLEIC ACID BASE; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE; PEGAPTANIB; RIBOZYME; SILICON DIOXIDE; SMALL INTERFERING RNA; TRIPLEX FORMING OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLON CANCER; CYSTIC FIBROSIS; CYTOMEGALOVIRUS RETINITIS; CYTOSKELETON; DIABETIC MACULAR EDEMA; DNA CLEAVAGE; DOWN REGULATION; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; GLIOBLASTOMA; HEART INFARCTION; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MICROBUBBLE; MULTIPLE MYELOMA; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RETINA MACULA EDEMA; TRANSCRIPTION INITIATION SITE; TRANSLATION INITIATION; UPREGULATION;

EID: 77953350228     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436210791112163     Document Type: Article

References (287)

1. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600.
2. Birikh KR, Heaton PA, Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur J Biochem 1997; 245: 1-16.
3. Symons RH. Small catalytic RNAs. Annu Rev Biochem 1992; 61: 641-71.
4. Vaish NK, Heaton PA, Fedorova O, Eckstein F. In vitro selection of a purine nucleotide specific hammerheadlike ribozyme. Proc Natl Acad Sci USA 1998; 95: 2158-162.
5. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334: 585-91.
6. Dahm SC, Uhlenbeck OC. Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 1991; 30: 9464-69.
7. Stage-Zimmermann TK, Uhlenbeck OC. Hammerhead ribozyme kinetics. RNA 1998; 4: 875-89.
8. Grassi G, Dawson P, Guarnieri G, Kandolf R, Grassi M. Therapeutic potential of hammerhead ribozymes in the treatment of hyper proliferative diseases. Curr Pharm Biotechnol 2004; 5: 369-86.
9. Grassi G, Grassi M, Platz J, Bauriedel G, Kandolf R, Kuhn A. Selection and characterization of active hammerhead ribozymes targeted against cyclin E and E2F1 full length mRNA. Antisense Nucleic Acid Drug Dev 2001; 11: 271-87.
10. Leopold LH, Shore SK, Newkirk TA, Reddy RM, Reddy EP. Multi unit ribozyme mediated cleavage of bcrabl mRNA in myeloid leukemias. Blood 1995; 85: 2162-70.
11. Scherr M, Grez M, Ganser A, Engels JW. Specific hammerhead ribozyme mediated cleavage of mutant Nras mRNA in vitro and ex vivo. Oligoribonucleotides as therapeutic agents. J Biol Chem 1997; 272: 14304-13.
12. Wiechen K, Zimmer C, Dietel M. Selection of a high activity cerbB-2 ribozyme using a fusion gene of cerbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther 1998; 5: 45-51.
13. Funato T, Ishii T, Kambe M, Scanlon KJ, Sasaki T. Anti K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther 2000; 7: 495-500.
14. Cheng J, Luo J, Zhang X, et al. Inhibition of cell proliferation in HCC 9204 hepatoma cells by a cmyc specific ribozyme. Cancer Gene Ther 2000; 7: 407-12.
15. Yang J, Pan WH, Clawson GA, Richmond A. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 2007; 67: 3127-34.
16. Samoto K, Ikezaki K, Ono M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55: 1189-93.
17. Kamochi J, Tokunaga T, Morino F, et al. Ribozyme mediated suppression of vascular endothelial growth factor gene expression enhances matrix metalloproteinase 1 expression in a human hepatocellular carcinoma cell line. Int J Oncol 2002; 21: 81-4.
18. Ke LD, Fueyo J, Chen X, et al. A novel approach to glioma gene therapy: down regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 1998; 12: 1391-6.
19. Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature 2002; 418: 252-8.
20. Fei Q, Zhang H, Fu L, et al. Experimental cancer gene therapy by multiple anti survivin hammerhead ribozymes. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 466-77.
21. Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme mediated reversal of the multidrug resistant phenotype. Proc Natl Acad Sci USA 1994; 91: 11123-7.
22. Funato T, Ishii T, Kanbe M, Scanlon KJ, Sasaki T. Reversal of cisplatin resistance in vivo by an anti fos ribozyme. In Vivo 1997; 11: 217-20.
23. Masuda Y, Kobayashi H, Holland JF, Ohnuma T. Reversal of multidrug resistance by a liposome MDR1 ribozyme complex. Cancer Chemother Pharmacol 1998; 42: 9-16.
24. Nagata J, Kijima H, Hatanaka H, et al. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance associated protein and multidrug resistance 1 gene. Int J Oncol 2002; 21: 1021-6.
25. Osada H, Tokunaga T, Abe Y, et al. Reversal of drug resistance mediated by hammerhead ribozyme against multidrug resistance associated protein 1 in a human glioma cell line. Int J Oncol 2003; 22: 823-7.
26. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002; 2: 257-65.
27. Kanazawa Y, Ohkawa K, Ueda K, et al. Hammerhead ribozyme mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996; 225: 570-6.
28. Wan MS, Fell PL, Akhtar S. Synthetic 2'-Omethyl modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev 1998; 8: 309-17.
29. Yokoyama Y, Wan X, Shinohara A, Takahashi Y, Tamaya T. Hammerhead ribozymes to modulate telomerase activity of endometrial carcinoma cells. Hum Cell 2001; 14: 223-31.
30. Folini M, Colella G, Villa R, Lualdi S, Daidone MG, Zaffaroni N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Invest Dermatol 2000; 114: 259-67.
31. Li S, Nosrati M, Kashani-Sabet M. Knockdown of telomerase RNA using hammerhead ribozymes and RNA interference. Methods Mol Biol 2007; 405: 113-31.
32. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension 1992; 20: 713-36.
33. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998; 81: 4E-6E.
34. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-26.
35. Dyson N. The regulation of E2F by pRB family proteins. Genes Dev 1998; 12: 2245-62.
36. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15: 2612-24.
37. Grassi G, Schneider A, Engel S, Racchi G, Kandolf R, Kuhn A. Hammerhead ribozymes targeted against cyclin E and E2F1 co operate to down regulate coronary smooth muscle cells proliferation. J Gene Med 2005; 7: 1223-34.
38. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-22.
39. Achenbach JC, Chiuman W, Cruz R, Li Y. DNAzymes: from creation in vitro to application in vivo. Curr Pharmaceut Biotechnol 2004; 5: 321-36.
40. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-6.
41. Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998; 37: 13330-42.
42. Warashina M, Kuwabara T, Nakamatsu Y, Taira K. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome. Chem Biol 1999; 6: 237-50.
43. Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS. Inhibition of bcrabl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther 1999; 10: 2847-57.
44. Liu C, Cheng R, Sun LQ, Tien P. Suppression of platelet type 12-lipoxygenase activity in human erythroleukemia cells by an RNA-cleaving DNAzyme. Biochem Biophys Res Commun 2001; 284: 1077-82.
45. Dass CR, Khachigian LM, Choong PF. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008; 7: 1909-12.
46. Qu Y, Zhang L, Mao M, et al. Effects of DNAzymes targeting Aurora kinase A on the growth of human prostate cancer. Cancer Gene Ther 2008; 15: 517-25.
47. Dass CR, Choong PF. C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies. Pharmazie 2008; 63: 411-4.
48. Benson VL, Khachigian LM, Lowe HC. DNAzymes and cardio vascular disease. Br J Pharmacol 2008; 154: 741-8.
49. Trepanier JB, Tanner JE, Alfieri C. Reduction in intracellular HCV RNA and virus protein expression in human hepatoma cells following treatment with 2' Omethyl modified anti core deoxyribozyme.Virology 2008; 377: 339-44.
50. Opalinska JB, Gewirtz AM. Nucleic acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1: 503-14.
51. Jorgensen R. Altered gene expression in plants due to trans interactions between homologous genes. Trends Biotechnol 1990; 8: 340-4.
52. Fire A. RNA triggered gene silencing. Trends Genet 1999; 15: 358-63.
53. Novina CD, Sharp PA. The RNAi revolution. Nature 2004; 430: 161-4.
54. Sharp PA. RNA interference 2001. Genes Dev 2001; 15: 485-90.
55. Poliseno L, Evangelista M, Mercatanti A, Mariani L, Citti L, Rainaldi G. The energy profiling of short interfering RNAs is highly predictive of their activity. Oligonucleotides 2004; 14: 227-32.
56. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22: 326-30.
57. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21 nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
58. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372: 143-9.
59. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21: 5716-24.
60. Heidenreich O. Oncogene suppression by small interfering RNAs. Curr Pharm Biotechnol 2004; 5: 349-54.
61. Cho S, Hartle L, Son S, et al. Delivery of small interfering RNA for the inhibition of ewndothelial cell apoptosis by hypoxia and serum deprivation. Biochem Biophys Res Commun 2008; 376: 153-8.
62. Spankuch B, Strebhardt K. Combinatorial application of nucleic acid based agents targeting protein kinases for cancer treatment. Curr Pharm Des 2008; 14: 1098-112.
63. Erb P, Ji J, Kump E, Mielgo A, Wernli M.Apoptosis and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008; 624: 283-95.
64. Guo X, Wang W, Zhou F, et al. siRNA mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol Ther 2008; 7: 1555-60.
65. Chen Y, Cheng G, Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res 2008; 25: 72-86.
66. Singh SK. RNA interference and its therapeutic potential against HIV infection. Expert Opin Biol Ther 2008; 8: 449-61.
67. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008; 78: 26-36.
68. Lang C, Sauter M, Szalay G, et al. Connective tissue growth factor: a crucial cytokine mediating cardiac fibrosis in ongoing enterovirus myocarditis. J Mol Med 2008; 86: 49-60.
69. Agostini F, Dapas B, Farra R, et al. Potential applications of small interfering RNAs in the cardiovascular field. Drug of the future 2006; 31: 513-25.
70. Dapas B, Farra R, Grassi M, et al. Role of the E2F1 cyclinE1 cyclinE2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its down regulation by siRNAs. Mol Med 2009; 15: 297-306.
71. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 2003; 99: 55-77.
72. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA like antisense drugs. J Biol Chem 2004; 279: 17181-9.
73. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347-55.
74. Larrouy B, Blonski C, Boiziau C, et al. RNase H mediated inhibition of translation by antisense oligodeoxyribonucleotides: use of backbone modification to improve specificity. Gene 1992; 121: 189-94.
75. Kole R, Sazani P. Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther 2001; 3: 229-34.
76. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-40.
77. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate early gene expression by an antisense oligonucleotide complementary to immediate early RNA. Antimicrob Agents Chemother 1996; 40: 2004-11.
78. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense cmyb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70.
79. Morishita R, Gibbons GH, Ellison KE, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8.
80. Morishita R, Gibbons GH, Ellison KE, et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonu cleotides. J Clin Invest 1994; 93: 1458-64.
81. Cioffi CL, Garay M, Johnston JF, et al. Selective inhibition of ARaf and C Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A Raf and C-Raf in serum-induced proliferation. Mol Pharmacol 1997; 51: 383-9.
82. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bclx expression induces apoptosis and regression of vascular disease. Nat Med 1998; 4: 222-7.
83. Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008; 113: 1857-87.
84. Liao Y, Tang ZY, Ye SL, Liu KD, Sun FX, Huang Z. Modulation of apoptosis, tumorigenesity and metastatic potential with antisense Hras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. Hepatogastroenterology 2000; 47: 365-70.
85. Ellouk-Achard S, Djenabi S, De Oliveira GA, et al. Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense cDNA. J Hepatol 1998; 29: 807-18.
86. Cheson BD. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther Clin Risk Manag 2007; 3: 855-70.
87. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-20.
88. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide Genta, G 3139, GC 3139, oblimersen sodium. Drugs R D 2007; 8: 321-34.
89. Gjertsen BT, Bredholt T, Anensen N, Vintermyr OK. Bcl 2 antisense in the treatment of human malignancies: a delusion in targeted therapy. Curr Pharm Biotechnol 2007; 8: 373-81.
90. Wetzler M, Donohue KA, Odenike OM, et al. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia Cancer and leukemia group B study 10107. Leuk Lymphoma 2008; 49: 1274-8.
91. Margolin K, Synold TW, Lara P, et al. Oblimersen and alpha interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol 2007; 133: 705-11.
92. Rudin CM, Salgia R, Wang X, et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oli gonucleotide oblimersen for extensive stage small cell lung cancer: CALGB 30103. J Clin Oncol 2008; 26: 870-6.
93. Moulder SL, Symmans WF, Booser DJ, et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 2008; 14: 7909-16.
94. Gekeler V, Gimmnich P, Hofmann HP, et al. G3139 and other CpG-containing immunostimulatory phosphorothioate oligode-oxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 2006; 16: 83-93.
95. Lee IK, Ahn JD, Kim HS, Park JY, Lee KU. Advantages of the circular dumbbell decoy in gene therapy and studies of gene regulation. Curr Drug Targets 2003; 4: 619-623.
96. Kukielka GL, Smith CW, LaRosa GJ, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995; 95: 89-103.
97. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. Long term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 2001; 121: 714-22.
98. Tomita N, Horiuchi M, Tomita S, et al. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am J Physiol 1998; 275: F278-84.
99. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-9.
100. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R. Long term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 2008; 10: 805-9.
101. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2008; 121: 1-13.
102. Bezzerri V, Borgatti M, Nicolis E, et al. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am J Respir Cell Mol Biol 2008; 39: 86-96.
103. Moriyama I, Ishihara S, Rumi MA, et al. Decoy oligodeoxynucleotide targeting activator protein 1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. Lab Invest 2008; 88: 652-63.
104. Cho JW, Cha YC, Lee KS. AP-1 transcription factor decoy reduces the TGF-beta1-induced cell growth in scleroderma fibroblasts through inhibition of cyclin E. Oncol Rep 2008; 19: 737-41.
105. Ahn JD, Kim CH, Magae J, et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun 2003; 310: 1048-53.
106. Gill JS, Zhu X, Moore MJ, Lu L, Yaszemski MJ, Windebank AJ. Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 2002; 23: 2773-81.
107. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 2008; 262: 201-13.
108. Gu J, Li G, Sun T, et al. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 2008; 89: 9-17.
109. Sen M, Tosca PJ, Zwayer C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009; 63: 983-95.
110. Rimmele M. Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 2003; 4: 963-71.
111. Scaggiante B, Dapas B, Grassi G, Manzini G. Interaction of Grich GT oligonucleotides with nuclear associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS J 2006; 273: 1350-61.
112. Berezovski M, Drabovich A, Krylova SM, et al. Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers. J Am Chem Soc 2005; 127: 3165-71.
113. Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998; 273: 20556-67.
114. Shukla D, Namperumalsamy P, Goldbaum M, Cunningham ET Jr. Pegaptanib sodium for ocular vascular disease. Indian J Ophthalmol 2007; 55: 427-30.
115. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LL. In vivo anticoagulant properties of a novel nucleotide based thrombin inhibitor and demonstration of regional anticoagulation in extracor poreal circuits. Blood 1993; 81: 3271-6.
116. Giangrande PH, Zhang J, Tanner A, et al. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci USA 2007; 104: 12988-93.
117. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 2003; 100: 15416-21.
118. Zhang L, Yoo S, Dritschilo A, Belyaev I, Soldatenkov V. Targeting Ku protein for sensitizing of breast cancer cells to DNA-damage. Int J Mol Med 2004; 14: 153-9.
119. Choi KH, Park MW, Lee SY, et al. Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer. Mol Cancer Ther 2006; 5: 2428-34.
120. Mi J, Zhang X, Rabbani ZN, et al. RNA aptamer targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008; 16: 66-73.
121. Sennino B, Falcon BL, McCauley D, et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007; 67: 7358-67.
122. Scaggiante B, Dapas B, Cristiano L, Grassi G. The Role of the eEF1A Family in Human Cancers. In: Malloy A, Carson E, Eds. Oncogene proteins: new research. New York 2007: 177-93.
123. Scaggiante B, Morassutti C, Dapas B, Tolazzi G, Ustulin F, Qua-drifoglio F. Human cancer cell lines growth inhibition by GTn oli-godeoxyribonucleotides recognizing single-stranded DNA-binding proteins. Eur J Biochem 1998; 252: 207-15.
124. Morassutti C, Dapas B, Scaggiante B, Paroni G, Xodo L, Quadrifoglio F. Effect of oligomer length and base substitutions on the cytotoxic activity and specific nuclear protein recognition of GTn oligonucleotides in the human leukemic CCRF-CEM cell line. Nucleosides Nucleotides 1999; 18: 1711-6.
125. Dapas B, Tell G, Scaloni A, et al. Identification of different isoforms of eEF1A in the nuclear fraction of human T-lymphoblastic cancer cell line specifically binding to aptameric cytotoxic GT oligomers. Eur J Biochem 2003; 270: 3251-62.
126. Bates PJ, Kahlon JB, Thomas SD, Trent JO, Miller DM. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999; 274: 26369-77.
127. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006; 5: 2957-62.
128. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 1997; 4: 809-16.
129. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med 2006; 47: 668-78.
130. Letai AG, Palladino MA, Fromm E, Rizzo V, Fresco JR. Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns. Biochemistry 1988; 27: 9108-12.
131. Felsenfeld G. DDRaRA. "Triple helix". J Am Chem Soc 1957; 79: 2023-4.
132. Goni JR, de lC, X, Orozco M.Triplex-forming oligonucleotide target sequences in the human genome. Nucleic Acids Res 2004; 32: 354-60.
133. Sun JS, Mergny JL, Lavery R, Montenay-Garestier T, Helene C. Triple helix structures: sequence dependence, flexibility and mismatch effects. J Biomol Struct Dyn 1991; 9: 411-24.
134. Giovannangeli C, Helene C. Triplex-forming molecules for modulation of DNA information processing. Curr Opin Mol Ther 2000; 2: 288-96.
135. Ziemba AJ, Reed MW, Raney KD, Byrd AB, Ebbinghaus SW. A bis-alkylating triplex forming oligonucleotide inhibits intracellular reporter gene expression and prevents triplex unwinding due to helicase activity. Biochemistry 2003; 42: 5013-24.
136. Liu J, Xu R, Jin Y, Wang D. Triplex targeting of human PDGF-B (c-sis, protooncogene) promoter specifically inhibits factors binding and PDGF-B transcription. Nucleic Acids Res 2001; 29: 783-91.
137. Kim HG, Miller DM. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry 1995; 34: 8165-71.
138. Scaggiante B, Morassutti C, Tolazzi G, Michelutti A, Baccarani M, Quadrifoglio F. Effect of unmodified triple helix-forming oligode-oxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells. FEBS Lett 1994; 352: 380-4.
139. Duca M, Vekhoff P, Oussedik K, Halby L, Arimondo PB. The triple helix: 50 years later, the outcome. Nucleic Acids Res 2008; 36: 5123-38.
140. Chin JY, Schleifman EB, Glazer PM. Repair and recombination induced by triple helix DNA. Front Biosci 2007; 12: 4288-97.
141. Cheng K, Ye Z, Guntaka RV, Mahato RI. Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 2006; 317: 797-805.
142. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siR-NAs. Nature 2004; 432: 173-8.
143. Kaneda Y. Gene therapy: a battle against biological barriers. Curr Mol Med 2001; 1: 493-9.
144. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm 2001; 229: 1-21.
145. Nishina K, Unno T, Uno Y, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008; 16: 734-40.
146. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003; 31: 589-95.
147. Hall AH, Wan J, Shaughnessy EE, Ramsay SB, Alexander KA. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 2004; 32: 5991-6000.
148. Geary RS, Yu RZ, Levin AA. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2001; 2: 562-73.
149. Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006; 16: 169-80.
150. Liu G. Technology evaluation: ISIS-113715, Isis. Curr Opin Mol Ther 2004; 6: 331-6.
151. Kraynack BA, Baker BF. Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Ar-gonaute2/eIF2C2-dependent activity. RNA 2006; 12: 163-76.
152. Schwarz DS, Tomari Y, Zamore PD. The RNA-induced silencing complex is a Mg2+-dependent endonuclease. Curr Biol 2004; 14: 787-91.
153. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-7.
154. Prakash TP, Kraynack B, Baker BF, Swayze EE, Bhat B. RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells. Bioorg Med Chem Lett 2006; 16: 3238-40.
155. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007; 117: 3615-22.
156. Iwase R, Toyama T, Nishimori K. Solid-phase synthesis of modified RNAs containing amide-linked oligoribonucleosides at their 3'-end and their application to siRNA. Nucleosides Nucleotides Nucleic Acids 2007; 26: 1451-4.
157. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003; 9: 1034-48.
158. Urban E, Noe CR. Structural modifications of antisense oligonu-cleotides. Farmaco 2003; 58: 243-58.
159. Choung S, Kim YJ, Kim S, Park HO, Choi YC. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 2006; 342: 919-27.
160. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003; 42: 7967-75.
161. Martin P. A New Access to 2-O-Alkylated Ribonucleosides and Properties of 2-O-Alkylated Oligoribonucleotides. Helv Chim Acta 1995; 78: 486-504.
162. Geary RS, Khatsenko O, Bunker K, Crooke R, Moore M, Burckin T, Truong L, Sasmor H, Levin AA. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J Pharmacol Exp Ther 2001; 296: 898-904.
163. Wang Z, Siwkowski A, Lima WF, Olsen P, Ravikumar VT. Antisense oligonucleotides: efficient synthesis of 2'-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1H-tetrazole as coupling activator? Bioorg Med Chem 2006; 14: 5049-60.
164. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006; 13: 496-502.
165. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA 2004; 10: 766-71.
166. Blidner RA, Hammer RP, Lopez MJ, Robinson SO, Monroe WT. Fully 2'-deoxy-2'-fluoro substituted nucleic acids induce RNA in-terference in mammalian cell culture. Chem Biol Drug Des 2007; 70: 113-22.
167. Wilds CJ, Damha MJ. 2'-Deoxy-2'-fluoro-beta-D-arabino-nucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. Nucleic Acids Res 2000; 28: 3625-35.
168. Watts JK, Choubdar N, Sadalapure K, et al. 2'-fluoro-4'-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res 2007; 35: 1441-51.
169. Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res 2006; 34: 1669-75.
170. Hoshika S, Minakawa N, Kamiya H, Harashima H, Matsuda A. RNA interference induced by siRNAs modified with 4'-thioribonucleosides in cultured mammalian cells. FEBS Lett 2005; 579: 3115-8.
171. Dande P, Prakash TP, Sioufi N, et al. Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications. J Med Chem 2006; 49: 1624-34.
172. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003; 21: 74-81.
173. Bondensgaard K, Petersen M, Singh SK, et al. Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity. Chemistry 2000; 6: 2687-95.
174. Braasch DA, Corey DR. Locked nucleic acid (LNA): finetuning the recognition of DNA and RNA. Chem Biol 2001; 8: 1-7.
175. Kaur H, Arora A, Wengel J, Maiti S. Thermodynamic, counterion, and hydration effects for the incorporation of locked nucleic acid nucleotides into DNA duplexes. Biochemistry 2006; 45: 7347-55.
176. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-70.
177. Mook OR, Baas F, de Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007; 6: 833-43.
178. Elmen J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005; 33: 439-47.
179. Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000; 97: 5633-8.
180. Jepsen JS, Pfundheller HM, Lykkesfeldt AE. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Oligonucleotides 2004; 14: 147-56.
181. Frieden M, Orum H. The application of locked nucleic acids in the treatment of cancer. IDrugs 2006; 9: 706-11.
182. Swayze EE, Siwkowski AM, Wancewicz EV, et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 2007; 35: 687-700.
183. Nielsen P, Egholm M, Berg R, Buchardt O. Peptide nucleic acids (PNA): oligonucleotide analogs with a polyamide backbone. In: Crooke S, Lebleu B, editors. Antisense Research and Applications. Boca Rato, FL: CRC Press 1993: 363-73.
184. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7: 187-95.
185. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1999; 1489: 141-58.
186. Arora V, Hannah TL, Iversen PL, Brand RM. Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res 2002; 19: 1465-70.
187. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003; 9: 2510-9.
188. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Wilton SD. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006; 8: 207-16.
189. Abes S, Moulton HM, Clair P, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116: 304-13.
190. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004; 558: 63-8.
191. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004; 14: 4975-7.
192. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 2006; 116: 123-9.
193. Jeong JH, Mok H, Oh YK, Park TG. siRNA conjugate delivery systems. Bioconjug Chem 2009; 20: 5-14.
194. Wu G, Yang W, Barth RF, et al. Molecular targeting and treatment of an epidermal growth factor receptor positive glioma using boronated cetuximab. Clin Cancer Res 2007; 13: 1260-8.
195. Ikeda Y, Taira K. Ligand targeted delivery of therapeutic siRNA. Pharm Res 2006; 23: 1631-40.
196. Cesarone G, Edupuganti OP, Chen CP, Wickstrom E. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease resistant IRS1 siRNA conjugated to a disulfide bridged D-peptide analogue of insulin like growth factor 1. Bioconjug Chem 2007; 18: 1831-40.
197. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34: e73.
198. Putnam D. Polymers for gene delivery across length scales. Nat Mater 2006; 5: 439-51.
199. Leonetti JP, Degols G, Lebleu B. Biological activity of oligonucleotide poly(Llysine) conjugates: mechanism of cell uptake. Bioconjug Chem 1990; 1: 149-53.
200. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005; 4: 581-93.
201. Miller AD. Cationic Liposomes for Gene Therapy. Angew Chem Int Ed 1998; 37: 1768-85.
202. Karmali PP, Chaudhuri A. Cationic liposomes as non viral carriers of gene medicines: resolved issues, open questions, and future promises. Med Res Rev 2007; 27: 696-722.
203. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid mediated DNA transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7.
204. Huang SL. Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1167-76.
205. Gershon H, Ghirlando R, Guttman SB, Minsky A. Mode of formation and structural features of DNA-cationic liposome complexes used for transfection. Biochemistry 1993; 32: 7143-51.
206. Radler JO, Koltover I, Salditt T, Safinya CR. Structure of DNA cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 1997; 275: 810-4.
207. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation induced damage when complexed to cationic liposomes. J Pharm Sci 1996; 85: 427-33.
208. Friend DS, Papahadjopoulos D, Debs RJ. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim Biophys Acta 1996; 1278: 41-50.
209. Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation mediated gene transfer. Proc Natl Acad Sci USA 1996; 93: 12349-54.
210. Lang I, Scholz M, Peters R. Molecular mobility and nucleocyto-plasmic flux in hepatoma cells. J Cell Biol 1986; 102: 1183-90.
211. Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1137-52.
212. Nyborg WL. Ultrasound, contrast agents and biological cells; a simplified model for their interaction during in vitro experiments. Ultrasound Med Biol 2006; 32: 1557-68.
213. Anwer K, Kao G, Proctor B, et al. Ultrasound enhancement of cationic lipid mediated gene transfer to primary tumors following systemic administration. Gene Ther 2000; 7: 1833-9.
214. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008; 60: 1278-88.
215. Burleigh MC, Dai S, Hagaman EW, Barnes CE, Xue ZL. Stepwise assembly of surface imprint sites on MCM-41 for selective metal ion separations. ACS Symphosium Series 2001; 778: 146-58.
216. Huh S, Wiench JW, Trewyn BG, Song S, Pruski M, Lin VS. Tuning of particle morphology and pore properties in mesoporous silicas with multiple organic functional groups. Chem Commun (Camb) 2003; 2364-5.
217. York AW, Kirkland SE, McCormick CL. Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli responsive drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1018-36.
218. Thurmond KB, Remsen EE, Kowalewski T, Wooley KL. Packaging of DNA by shell crosslinked nanoparticles. Nucleic Acids Res 1999; 27: 2966-71.
219. Jewell CM, Lynn DM. Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid based therapeutics. Adv Drug Deliv Rev 2008; 60: 979-99.
220. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005; 57: 2177-202.
221. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower-generation polypropylenimine dendrimers are effective genetransfer agents. Pharm Res 2002; 19: 960-7.
222. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 1996; 30: 53-65.
223. Haensler J, Szoka FC, Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem 1993; 4: 372-9.
224. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci USA 1999; 96: 5177-81.
225. Braun CS, Vetro JA, Tomalia DA, Koe GS, Koe JG, Middaugh CR. Structure/function relationships of polyamidoamine/DNA den drimers as gene delivery vehicles. J Pharm Sci 2005; 94: 423-36.
226. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release 2001; 73: 401-16.
227. Li J, Loh XJ. Cyclodextrin based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1000-17.
228. Davis ME, Brewster ME. Cyclodextrin based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004; 3: 1023-35.
229. Yang C, Li H, Goh SH, Li J. Cationic star polymers consisting of alpha-cyclodextrin core and oligoethylenimine arms as nonviral gene delivery vectors. Biomaterials 2007; 28: 3245-54.
230. Li J, Yang C, Li HZ, et al. Cationic supramolecules composed of multiple oligoethylenimine-grafted beta-cyclodextrins threaded on a polymer chain for efficient gene delivery. Adv Mater 2006; 18: 2969-74.
231. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006; 58: 467-86.
232. Midoux P, Mendes C, Legrand A, et al. Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucleic Acids Res 1993; 21: 871-8.
233. Lee H, Jeong JH, Park TG. A new gene delivery formulation of polyethylenimine/DNA complexes coated with PEG conjugated fusogenic peptide. J Control Release 2001; 76: 183-92.
234. Rolland AP, Mumper RJ. Plasmid delivery to muscle: Recent advances in polymer delivery systems. Adv Drug Deliv Rev 1998; 30: 151-72.
235. Lee KY, Kwon IC, Kim YH, Jo WH, Jeong SY. Preparation of chitosan self-aggregates as a gene delivery system. J Control Release 1998; 51: 213-20.
236. Hernot S, Klibanov AL. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008; 60: 1153-66.
237. Chomas JE, Dayton P, Allen J, Morgan K, Ferrara KW. Mechanisms of contrast agent destruction. IEEE Trans Ultrason Ferroe lectr Freq Control 2001; 48: 232-48.
238. Christiansen JP, French BA, Klibanov AL, Kaul S, Lindner JR. Targeted tissue transfection with ultrasound destruction of plasmid bearing cationic microbubbles. Ultrasound Med Biol 2003; 29: 1759-67.
239. Teupe C, Richter S, Fisslthaler B, et al. Vascular gene transfer of phosphomimetic endothelial nitric oxide synthase (S1177D) using ultrasound-enhanced destruction of plasmid-loaded microbubbles improves vasoreactivity. Circulation 2002; 105: 1104-9.
240. Mayer CR, Bekeredjian R. Ultrasonic gene and drug delivery to the cardiovascular system. Adv Drug Deliv Rev 2008; 60: 1177-92.
241. Abbas AO, Donovan MD, Salem AK. Formulating poly(lactide co glycolide) particles for plasmid DNA delivery. J Pharm Sci 2008; 97: 2448-61.
242. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endolysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002; 16: 1217-26.
243. Wattiaux R, Laurent N, Wattiaux-De Coninck S, Jadot M. Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 2000; 41: 201-8.
244. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 2000; 97: 811-6.
245. De Laporte L, Shea LD. Matrices and scaffolds for DNA delivery in tissue engineering. Adv Drug Deliv Rev 2007; 59: 292-307.
246. Grassi M, Grassi G, Lapasin R, Colombo I. Understanding Drug Release and Absorption Mechanisms. Boca Raton: CRC Press 2007.
247. Davia L, Grassi G, Pontrelli G, Lapasin R, Perin D, Grassi M. Mathematical modelling of NABD release from endoluminal gel paved stent. Comput Biol Chem 2008; 33: 33-40.
248. Kimura T, Iwai S, Moritan T, et al. Preparation of poly(vinyl alcohol)/DNA hydrogels via hydrogen bonds formed on ultra-high pressurization and controlled release of DNA from the hydrogels for gene delivery. J Artif Organs 2007; 10: 104-8.
249. Kong HJ, Kim ES, Huang YC, Mooney DJ. Design of biodegradable hydrogel for the local and sustained delivery of angiogenic plasmid DNA. Pharm Res 2008; 25: 1230-8.
250. Cohen-Sacks H, Elazar V, Gao J, et al. Delivery and expression of pDNA embedded in collagen matrices. J Control Release 2004; 95: 309-20.
251. Mahato RI, Anwer K, Tagliaferri F, et al. Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. Hum Gene Ther 1998; 9: 2083-99.
252. Mahato RI, Takakura Y, Hashida M. Development of targeted delivery systems for nucleic acid drugs. J Drug Target 1997; 4: 337-57.
253. Chono S, Li SD, Conwell CC, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 2008; 131: 64-9.
254. Auguste DT, Furman K, Wong A, et al. Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J Control Release 2008; 130: 266-74.
255. Susa T, Kato T, Kato Y. Reproducible transfection in the presence of carrier DNA using FuGENE6 and Lipofectamine2000. Mol Biol Rep 2008; 35: 313-9.
256. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 2006; 112: 229-39.
257. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006; 13: 1222-34.
258. Zimmer A, Aziz SA, Gilbert M, Werner D, Noe CR. Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides. Eur J Pharm Biopharm 1999; 47: 175-8.
259. Junghans M, Loitsch SM, Steiniger SC, Kreuter J, Zimmer A. Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. Eur J Pharm Biopharm 2005; 60: 287-94.
260. Moriguchi R, Kogure K, Akita H, et al. A multifunctional enve-lope-type nano device for novel gene delivery of siRNA plasmids. Int J Pharm 2005; 301: 277-85.
261. Negishi Y, Endo Y, Fukuyama T, et al. Delivery of siRNA into the cytoplasm by liposomal bubbles and ultrasound. J Control Release 2008; 132: 124-30.
262. Hashiya N, Aoki M, Tachibana K, et al. Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model. Biochem Biophys Res Commun 2004; 317: 508-14.
263. Inoue Y, Kurihara R, Tsuchida A, et al. Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J Control Release 2008; 126: 59-66.
264. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 2008; 129: 107-16.
265. Patil ML, Zhang M, Betigeri S, Taratula O, He H, Minko T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 2008; 19: 1396-403.
266. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006; 17: 751-66.
267. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12: 461-6.
268. Wang DA, Narang AS, Kotb M, et al. Novel branched poly (ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 2002; 3: 1197-207.
269. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 2005; 7: E61-77.
270. Zintchenko A, Philipp A, Dehshahri A, Wagner E. Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. Bioconjug Chem 2008; 19: 1448-55.
271. Santhakumaran LM, Thomas T, Thomas TJ. Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers. Nucleic Acids Res 2004; 32: 2102-12.
272. Choi Y, Thomas T, Kotlyar A, Islam MT, Baker JR, Jr. Synthesis and functional evaluation of DNA-assembled polyamidoamine den-drimer clusters for cancer cell-specific targeting. Chem Biol 2005; 12: 35-43.
273. Kang H, DeLong R, Fisher MH, Juliano RL. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 2005; 22: 2099-106.
274. Eom KD, Park SM, Tran HD, Kim MS, Yu RN, Yoo H. Dendritic alpha,epsilon-poly(L-lysine)s as delivery agents for antisense oli-gonucleotides. Pharm Res 2007; 24: 1581-9.
275. Weber N, Ortega P, Clemente MI, et al. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J Control Release 2008; 132: 55-64.
276. Kim SH, Jeong JH, Ou M, Yockman JW, Kim SW, Bull DA. Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis. Biomaterials 2008; 29: 4439-46.
277. El Andaloussi S, Johansson H, Magnusdottir A, Jarver P, Lundberg P, Langel U. TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J Control Release 2005; 110: 189-201.
278. Ayers D, Cuthbertson J, Schroy K, Sullivan S. Polyacrylic acid mediated ocular dlivery of ribozymes. J Control Release 1996; 38: 167-75.
279. Zhang Z, Cao X, Zhao X, Holt CM, Lewis AL, Lu JR. Controlled delivery of antisense oligodeoxynucleotide from multilayered bio-compatible phosphorylcholine polymer films. J Control Release 2008; 130: 69-76.
280. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998; 81: 4E-6E.
281. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-95.
282. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of paients with de novo coronary artery lesions) substudy. Circulation 2004; 109: 2273-8.
283. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 2007; 115: 1433-9.
284. Grassi G, Farra R, Noro E, et al. Charactherization of nucleid acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices. J Drug Deliv Sci Technol 2007; 17: 325-31.
285. Grassi G, Crevatin A, Farra R, et al. Rheological properties of aqueous Pluronic-alginate systems containing liposomes. J Colloid Interface Sci 2006; 301: 282-90.
286. Davia L, Grassi G, Pontrelli G, Lapasin R, Perin D, Grassi M. Mathematical modelling of NABD release from endoluminal gel paved stent. Comput Biol Chem 2008; 33: 33-40.
287. Grassi M, Pontrelli G, Teresi L, et al. Novel design of drug delivery in stented arteries: a numerical comparative study. Math Biol Eng 2009 2009; 6: 493-508.